Unlocking the Next Generation of Complement Therapies
Neurodegeneration β’ Autoimmune β’ Ophthalmology
51 - 200
π° $130M Post-IPO Equity on 2022-07
Yesterday
51 - 200
Vice President, Market Access leads strategy for Annexon's novel therapies.
πΊπΈ United States β Remote
π΅ $329k - $365k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π΄ Lead
π Vice President
2 days ago
51 - 200
Lead quality systems at a biopharmaceutical company enhancing compliance and processes.
πΊπΈ United States β Remote
π΅ $228k - $255k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π Senior
π¬ Director
3 days ago
51 - 200
Vice President of Marketing for biotech company targeting neuroinflammatory diseases.
πΊπΈ United States β Remote
π΅ $298k - $330k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π΄ Lead
π‘ Marketing
3 days ago
51 - 200
Lead commercial ops for product launch at Annexon Biosciences.
πΊπΈ United States β Remote
π΅ $270k - $330k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π΄ Lead
βοΈ Operations
4 days ago
51 - 200
Lead analytics and market research initiatives at Annexon for commercial insights.
πΊπΈ United States β Remote
π΅ $249k - $300k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π΄ Lead
π¬ Director
5 days ago
51 - 200
Lead payer strategies for reimbursement of Annexon Biosciences' therapies.
πΊπΈ United States β Remote
π΅ $225k - $275k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π Senior
π‘ Marketing
October 15
51 - 200
Lead marketing strategies targeting healthcare professionals for Annexon Biosciences.
πΊπΈ United States β Remote
π΅ $249k - $300k / year
π° $130M Post-IPO Equity on 2022-07
β° Full Time
π΄ Lead
π‘ Marketing